Who are Granulocyte-colony stimulating growth factor's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gm-Csf, Interleukin-3, Interferon-Alpha, Late receiving G-CSF group, vunakizumab and recaticimab., PUVA (8MOP + UVA) + IFN.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/granulocyte-colony-stimulating-growth-factor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Granulocyte-colony stimulating growth factor — Competitive Intelligence Brief

Granulocyte-colony stimulating growth factor (Granulocyte-colony stimulating growth factor) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytokine; Hematopoietic growth factor. Area: Oncology; Hematology.

phase 3 Cytokine; Hematopoietic growth factor G-CSF receptor (CSF3R) Oncology; Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Granulocyte-colony stimulating growth factor (Granulocyte-colony stimulating growth factor) — Hellenic Oncology Research Group. Granulocyte-colony stimulating factor (G-CSF) stimulates the bone marrow to produce and release neutrophils, increasing white blood cell counts.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Granulocyte-colony stimulating growth factor TARGET	Granulocyte-colony stimulating growth factor	Hellenic Oncology Research Group	phase 3	Cytokine; Hematopoietic growth factor	G-CSF receptor (CSF3R)
Gm-Csf	gm-csf	Pfizer	marketed	cytokine	GM-CSF receptor	1991-01-01
Interleukin-3	Interleukin-3	Sandoz	marketed	Cytokine	IL-3 receptor (CD123)
Interferon-Alpha	Interferon-Alpha	University of Birmingham	marketed	Cytokine; Immunomodulator	Interferon-alpha receptor (IFNAR)
Late receiving G-CSF group	Late receiving G-CSF group	Department of Medical Services Ministry of Public Health of Thailand	marketed	Cytokine; Hematopoietic growth factor	G-CSF receptor (GCSFR)
vunakizumab and recaticimab.	vunakizumab and recaticimab.	Xiangya Hospital of Central South University	marketed	Monoclonal antibody (anti-cytokine)	IL-12/IL-23 p40 subunit (vunakizumab); TNF-α (recaticimab)
PUVA (8MOP + UVA) + IFN	PUVA (8MOP + UVA) + IFN	Madrilenian Group of Cutaneous Lymphomas	marketed	Photochemotherapy + cytokine combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytokine; Hematopoietic growth factor class)

Department of Medical Services Ministry of Public Health of Thailand · 2 drugs in this class
Hellenic Oncology Research Group · 1 drug in this class
University of Southern California · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Granulocyte-colony stimulating growth factor — Competitive Intelligence Brief. https://druglandscape.com/ci/granulocyte-colony-stimulating-growth-factor. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab